Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the ... to include neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disorder ...

Eculizumab, which is approved for neuromyelitis optica spectrum disorder (NMOSD) and other indications ... the complement ...

A swift and accurate diagnosis is crucial when treating any disease, but especially a rare one. Sadly, people with particularly rare diseases that present like more recognisable conditions face a ...